News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
15 Jan 2026
byAudrey Abella
In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).








